Published in Reumatismo on June 28, 2005
Addition of Aerobic Training to Conventional Rehabilitation After Femur Fracture | NCT04025866
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Early and late mortality in elderly patients after hip fracture: a cohort study using administrative health databases in the Lazio region, Italy. BMC Geriatr (2011) 1.13
Proximal femural fractures: epidemiology. Clin Cases Miner Bone Metab (2009) 0.80
Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of. Clin Cases Miner Bone Metab (2011) 0.80
Fracture prevention service to bridge the osteoporosis care gap. Clin Interv Aging (2015) 0.77
The impact of different rehabilitation strategies after major events in the elderly: the case of stroke and hip fracture in the Tuscany region. BMC Health Serv Res (2007) 0.76
Severe osteoporosis: diagnosis of femoral fractures. Clin Cases Miner Bone Metab (2010) 0.75
New dosing options in osteoporosis treatment: clinical evidence on Risedronate 75mg monthly treatment. Clin Cases Miner Bone Metab (2008) 0.75
The initiative on hip fractures of the Veneto Region. Clin Cases Miner Bone Metab (2012) 0.75
Counseling, quality of life, and acute postoperative pain in elderly patients with hip fracture. J Multidiscip Healthc (2013) 0.75
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2003) 3.33
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab (2000) 2.67
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest (2006) 2.53
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ (1997) 2.21
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem (1999) 1.89
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas) J Clin Endocrinol Metab (1994) 1.58
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol (2001) 1.50
Bone loss in response to long-term glucocorticoid therapy. Bone Miner (1990) 1.44
Different patterns of steroid secretion in patients with adrenal incidentaloma. J Clin Endocrinol Metab (1996) 1.43
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab (1999) 1.43
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest (2003) 1.40
Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH Registry. J Endocrinol Invest (2006) 1.39
Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. J Clin Endocrinol Metab (1997) 1.39
Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int (2009) 1.36
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
The vascularization of the vertebral body in the human fetus at term. Clin Orthop Relat Res (1969) 1.29
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res (1998) 1.18
Radioimmunoassay of 1,25-dihydroxy vitamin D2: studies on the metabolism of vitamin D2 in man. Clin Endocrinol (Oxf) (1983) 1.13
Short term ethanol ingestion can affect the testicular response to single-dose human chorionic gonadotropin in normal subjects. J Endocrinol Invest (1986) 1.12
Hypomagnesaemia: studies of parathyroid hormone secretion and function. Clin Endocrinol (Oxf) (1984) 1.08
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis (2004) 1.06
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab (2000) 1.05
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int (2012) 1.05
Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer (2001) 1.05
Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int (2007) 1.03
Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone (2004) 1.02
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis (2008) 1.02
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol (1985) 1.02
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer (2005) 1.01
Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis (2007) 1.01
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer (2005) 1.00
Relation between adiponectin and bone mineral density in elderly post-menopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. J Endocrinol Invest (2008) 1.00
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst (1996) 0.99
Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther (1978) 0.99
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer (1998) 0.98
Endoscopic diagnosis and treatment of gastric bezoars. Gastrointest Endosc (1998) 0.98
Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol (2001) 0.98
Serum angiotensin converting enzyme (ACE) in silicosis. Eur J Respir Dis (1984) 0.98
Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med (2010) 0.98
Natural killer cell activity and sensitivity to positive and negative modulation in uncomplicated obese subjects: relationships to leptin and diet composition. Int J Obes Relat Metab Disord (2004) 0.97
The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. Clin Endocrinol (Oxf) (2001) 0.96
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int (2001) 0.96
Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int (2004) 0.95
Age-related cortical bone loss at the metacarpal. Calcif Tissue Int (1997) 0.95
Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men. Calcif Tissue Int (2002) 0.95
[Antioxidant action of gabexate mesilate (Foy) in an experimental model of endotoxic shock]. Minerva Anestesiol (1995) 0.95
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol (2001) 0.95
In-situ polymerization behaviour of bone cements. J Mater Sci Mater Med (1997) 0.95
Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res (1994) 0.94
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res (1994) 0.94
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol (1994) 0.94
Association of CTR and COLIA1 alleles with BMD values in peri- and postmenopausal women. Calcif Tissue Int (2000) 0.93
Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest (1995) 0.93
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res (2001) 0.93
Increase in RNA and protein synthesis by mitochondria irradiated with helium-neon laser. Biochem Biophys Res Commun (1989) 0.93
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int (1986) 0.92
Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. Eur J Appl Physiol (2004) 0.92
Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology (2001) 0.91
Familial benign hypercalcaemia. Study of a large family. Q J Med (1983) 0.91
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer (1996) 0.91
Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab (2001) 0.91
Clinical manifestations, co-sensitizations, and immunoblotting profiles of buckwheat-allergic patients. Allergy (2010) 0.90
Once-a-day neurally stimulated and basal ACTH secretion phases in man and their response to corticoid inhibition. J Clin Endocrinol Metab (1969) 0.89
Cytochemical bioassay of parathyroid hormone in maternal and cord blood. Arch Dis Child (1985) 0.88
Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital J Gastroenterol Hepatol (1997) 0.88
Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res (2000) 0.88
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia (2006) 0.88
Congenital syphilis in Italy. Sex Transm Infect (2007) 0.88
New perspectives on the definition and the management of severe osteoporosis: the patient with two or more fragility fractures. J Endocrinol Invest (2009) 0.88
Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis. Clin Exp Allergy (2010) 0.87
Quantitative ultrasound calcaneous measurements: normative data for the Italian population. the ESOPO study. J Clin Densitom (2007) 0.87